Halda Therapeutics Appoints Christian Schade as CEO, Signaling Next Stage of Growth
Slice of Healthcare Team
Oct 04, 2024
Key Highlights
- Halda Therapeutics names Christian Schade as President and CEO.
- Schade brings over 20 years of biotech leadership experience.
- RIPTAC™ cancer therapies on track for clinical trials in 2025.
- Focus on prostate and breast cancer treatments with unmet needs.
Source: Business Wire
Notable Quotes
“ With Chris’ outstanding leadership, Halda is well positioned to realize the full potential of the RIPTAC modality. ”
Tim Shannon, Chair of Halda’s Board of Directors at Canaan Partners
“ I am delighted to join the talented team at Halda that has made impressive progress advancing the RIPTAC platform. ”
Christian Schade, President and CEO at Halda Therapeutics
-2e14ed90-63f5-4ce1-84fc-3fa9506b84be.png&w=3840&q=75)
